Vanguard reports 6.61M shares (5.09%) of NeoGenomics
NeoGenomics Inc Schedule 13G shows Vanguard Capital Management beneficially owns 6,610,272 shares of Common Stock, representing 5.09% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NeoGenomics Inc Schedule 13G shows Vanguard Capital Management beneficially owns 6,610,272 shares of Common Stock, representing 5.09% of the class.
The filing lists sole dispositive power over 6,610,272 shares and sole voting power over 954,449 shares, and is signed on 04/30/2026.
Insights
Passive institutional stake exceeding 5% reported by Vanguard.
The Schedule 13G filing documents that Vanguard Capital Management holds 6,610,272 shares, a 5.09% position in NeoGenomics Common Stock. Schedule 13G status typically indicates passive investment intent under SEC rules.
Voting and dispositive power figures are disclosed: sole voting power 954,449 and sole dispositive power 6,610,272. Subsequent filings may show changes in ownership or a shift to Schedule 13D if intent becomes active.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned regulatory
Sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Vanguard report for NEO ownership?
Who filed the Schedule 13G for NEO?
How much voting and dispositive power does Vanguard report for NEO?
Does this Schedule 13G indicate active control of NeoGenomics?
AI-generated analysis. How Rhea-AI works. Not financial advice.